Enhancing the Efficacy of Chemotherapeutic Breast Cancer Treatment with Nonanticoagulant Heparins; Annual rept. 15 Apr 2007-14 Apr 2008

摘要

A mouse model of breast cancer with human breast cancer cell lines MCF7 (wild type) or MCF7-doxorubicin resistant (MCF7-R) cells was used evaluate the efficacy of low molecular weight heparins (LMWH) either alone or in combination with doxorubicin to prevent tumor growth. Tumor volume measurements were performed at intervals throughout the course of treatment. LMWH compounds (Enoxaparin or non-anticoagulant heparin NACH) given together with chemotherapeutic agent doxorubicin decreased tumor growth rate and prolong survival in animals bearing MCF7 wild-type tumors. These agents appeared to be less effective in animals bearing doxorubicin-resistant tumors. Bleeding times determined on animals in all treatment groups showed that there were no statistically significant differences among the groups. However, animals in ENOX groups showed increased bruising at the sites of injection. These studies will be repeated, and studies with alpha v beta 3-targeted nanoparticle formulations will be performed to compare the efficacies of non-targeted and targeted therapies.